Avastin fails to win FDA panel support

12/5/2007 | Wall Street Journal (free content), The · NYTimes.com

An FDA advisory panel voted 5-4 Wednesday against approving Genentech's cancer drug Avastin as a first-line treatment for patients with recurrent or metastatic breast cancer. A National Cancer Institute study showed no significant difference in overall survival for patients who took Avastin with Taxol compared to those taking Taxol alone.

View Full Article in:

Wall Street Journal (free content), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR